# MHB039A

Source: https://onco.cc/drugs/mhb039a/  
OnCo record `mhb039a` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MHB039A is a bispecific antibody from Minghui Pharmaceutical (Hangzhou) Ltd, in registered phase 2 trials for metastatic cancer.

## Summary

MHB039A is listed on ClinicalTrials.gov as an intervention in 4 registered phase 2 trials sponsored by Minghui Pharmaceutical (Hangzhou) Ltd, in metastatic cancer. A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: MHB039A
- Modality: Bispecific antibody
- Mechanism: A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway.

## Sources

- ClinicalTrials.gov: trials of MHB039A: https://clinicaltrials.gov/search?intr=MHB039A

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- trials: [A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer](https://onco.cc/trials/nct07229599/), [A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors](https://onco.cc/trials/nct07130383/), [A Study of MHB039A for Advanced Solid Tumor](https://onco.cc/trials/nct06345482/), [A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors](https://onco.cc/trials/nct07126665/)

---
JSON: https://onco.cc/api/v1/entities/mhb039a.json